Abstract
At least two different types of sigma σ (σ1 and σ2) receptors have been identified. A structural feature common to high-affinity (Ki < 10 nM) σ1 ligands is: C-N(R)-X-Ph; both C and Ph are associated with regions of bulk tolerance. Numerous other ligands bind, but typically do so with lower affinity.
Keywords: sigma receptors, arylalkylamines, arylpentylamines piperazines, piperidines, pharmacophore
Mini-Reviews in Medicinal Chemistry
Title: Pharmacophore Identification for Sigma-1 (σ1) Receptor Binding: Application of the "Deconstruction - Reconstruction - Elaboration" Approach
Volume: 5 Issue: 10
Author(s): R. A. Glennon
Affiliation:
Keywords: sigma receptors, arylalkylamines, arylpentylamines piperazines, piperidines, pharmacophore
Abstract: At least two different types of sigma σ (σ1 and σ2) receptors have been identified. A structural feature common to high-affinity (Ki < 10 nM) σ1 ligands is: C-N(R)-X-Ph; both C and Ph are associated with regions of bulk tolerance. Numerous other ligands bind, but typically do so with lower affinity.
Export Options
About this article
Cite this article as:
Glennon A. R., Pharmacophore Identification for Sigma-1 (σ1) Receptor Binding: Application of the "Deconstruction - Reconstruction - Elaboration" Approach, Mini-Reviews in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/138955705774329519
DOI https://dx.doi.org/10.2174/138955705774329519 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Recent Understanding of Leukocytapheresis (LCAP) for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Subject Index To Volume 6
Current Gene Therapy The Retinal Pigment Epithelium in Health and Disease
Current Molecular Medicine The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Glutamatergic Animal Models of Schizophrenia
Current Pharmaceutical Design Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Small Conductance Ca2+-Activated K+ Channels as Targets of CNS Drug Development
Current Drug Targets - CNS & Neurological Disorders Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Theory of Mind is Just Behavior
Current Psychiatry Reviews Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders
Current Drug Metabolism Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior
Current Drug Delivery Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design